Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Living Cell Technologies ( (AU:1AI) ) just unveiled an announcement.
Algorae Pharmaceuticals has secured a A$3.0 million receivables-based working capital facility from ScotPac Business Finance for an initial 24-month term, providing a revolving, non-dilutive source of funding that can be drawn and repaid flexibly with interest charged only on utilised amounts. The facility, secured against AlgoraeRx’s trade receivables and backed by a parent guarantee, is intended to bolster the company’s working capital, enabling faster inventory deployment and execution of supply opportunities, thereby supporting the scaling of its revenue-generating commercialisation operations across Australia and New Zealand and strengthening its financial flexibility without issuing new equity.
The most recent analyst rating on (AU:1AI) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Living Cell Technologies stock, see the AU:1AI Stock Forecast page.
More about Living Cell Technologies
Algorae Pharmaceuticals is an AI-enabled pharmaceutical company focused on drug-combination discovery and pharmaceutical commercialisation. Its proprietary AI platform, AlgoraeOS, is used to identify synergistic drug combinations and guide preclinical experimental design, while its commercial arm, AlgoraeRx, sources, licenses and supplies generic and specialty medicines across Australia and New Zealand through manufacturing partners and established distribution channels.
YTD Price Performance: 21.43%
Average Trading Volume: 2,383,652
Technical Sentiment Signal: Buy
Current Market Cap: A$28.71M
See more data about 1AI stock on TipRanks’ Stock Analysis page.